Are you Dr. Konno?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 25 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
550 1st Ave
New York, NY 10016Phone+1 212-263-5506
Summary
- Dr. Fumiko Konno, MD is a board certified pathologist in New York, New York. She is currently licensed to practice medicine in New York, Florida, and Oregon. She is affiliated with New York-Presbyterian Hospital and New York-Presbyterian Queens.
Education & Training
- Memorial Sloan Kettering Cancer Center Oncologic PathologyFellowship, Selective Pathology, 2013 - 2014
- NYU Grossman School of MedicineResidency, Pathology-Anatomic and Clinical, 2009 - 2013
- Drexel University College of MedicineClass of 2009
Certifications & Licensure
- DC State Medical License 2022 - 2026
- MD State Medical License 2016 - 2026
- NY State Medical License 2013 - 2026
- VA State Medical License 2022 - 2026
- FL State Medical License 2023 - 2025
- NJ State Medical License 2016 - 2025
- OR State Medical License 2023 - 2025
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Cytopathology
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsCytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications.Darren J. Buonocore, Fumiko Konno, Achim A. Jungbluth, Denise Frosina, Mariam Fayad
Cancer Cytopathology. 2019-10-01 - 10 citationsImmunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.Dara S. Ross, Ahmet Zehir, Edi Brogi, Fumiko Konno, Melissa Krystel-Whittemore
Modern Pathology. 2019-01-01 - 8 citationsCytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma.Fresia Pareja, Melissa Murray, Ryan Des Jean, Fumiko Konno, Maria A. Friedlander
Journal of the American Society of Cytopathology. 2017-01-01